NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES
THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.
- Dr. Fabrice NAVARRO, New Deal Project Coordinator
THE PROJECT GOALS
THE PROJECT GOALS
The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.
Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.
Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.
THE PROJECT NEWS
October New Deal Reads
Extracellular Vesicles With Possible Roles in Gut Intestinal Tract Homeostasis and IBD. Chang, X. et al. Mediators of [...]
From the lab to the market: regulations and development of new treatments.
Translating research ideas into prescription medicines is a long journey that can take between 12 to 15 years [...]
September New Deal Reads
Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors. Garrido-Trigo A. and Salas A. [...]
COVID-19 and Inflammatory Bowel Disease: an insight into the relationship between conditions
In December 2019 the now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in Wuhan. Since [...]
THE PROJECT PARTNERS
THE PROJECT PARTNERS
